MaaT Pharma Safety board recommends MaaT033 phase 2b continues as planned

MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB review is expected in 1Q26, while topline efficacy results should come in 2H27. In the near-term, we look forward to data for MaaT013 in metastatic melanoma in 2H25, as well as the full overall survival data (OS) from the phase 3 trial of MaaT013 in aGvHD by YE25. €17 TP and BUY maintained.